MAP2K7 and melanoma: Two ongoing phase I/II clinical trials are proceeding in NRAS-mutant melanoma combining MEK inhibitors with CDK4/6 inhibitors with promising early results: 1) binimetinib and LEE011 and 2) trametinib and palbociclib.